KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to -$1.5 billion.

  • Gilead Sciences' Cash from Financing Activities fell 797.68% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2 billion, marking a year-over-year increase of 3783.86%. This contributed to the annual value of -$3.4 billion for FY2024, which is 3301.46% up from last year.
  • Per Gilead Sciences' latest filing, its Cash from Financing Activities stood at -$1.5 billion for Q3 2025, which was down 797.68% from -$1.6 billion recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Cash from Financing Activities ranged from a high of $2.3 billion in Q4 2024 and a low of -$3.5 billion during Q3 2021
  • Moreover, its 5-year median value for Cash from Financing Activities was -$1.5 billion (2023), whereas its average is -$1.6 billion.
  • In the last 5 years, Gilead Sciences' Cash from Financing Activities crashed by 158244.27% in 2021 and then surged by 30564.15% in 2024.
  • Gilead Sciences' Cash from Financing Activities (Quarter) stood at -$1.9 billion in 2021, then rose by 19.98% to -$1.6 billion in 2022, then rose by 29.28% to -$1.1 billion in 2023, then soared by 305.64% to $2.3 billion in 2024, then plummeted by 165.88% to -$1.5 billion in 2025.
  • Its last three reported values are -$1.5 billion in Q3 2025, -$1.6 billion for Q2 2025, and -$3.4 billion during Q1 2025.